Belgian Diversified Financial Stock News

Azelis Group (ENXTBR:AZE) shares have recently caught the attention of market watchers, with moves in the stock price reflecting a broader pattern in the specialty chemicals sector. Trading activity suggests investors are weighing up the company’s most recent business fundamentals. See our latest analysis for Azelis Group. Azelis Group’s 1-year total shareholder return of -48.71% reflects a tough stretch for the business, with momentum clearly fading as the stock’s YTD share price return sits...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Key Insights The projected fair value for Melexis is €54.64 based on 2 Stage Free Cash Flow to Equity With €55.65 share...

KBC Group NV reported third quarter and nine-month earnings for the period ended September 30, 2025, with net income rising to €1.00 billion for the quarter and €2.57 billion for the nine months, both higher than the same periods last year. The company's earnings per share from continuing operations also increased over both periods, reflecting improved profitability and operational performance. We'll assess how the jump in net income and earnings per share informs KBC Group's ongoing...

Noveon Magnetics and Solvay recently announced a multi-year supply agreement for light and heavy rare earth oxides, with Solvay providing Neodymium-Praseodymium, Dysprosium, and Terbium oxides, sourced partly from recycled materials, to support Noveon's production of permanent magnets starting in 2026. This collaboration advances a more resilient and sustainable domestic supply chain for rare earth magnets amid ongoing global supply risks and growing demand. The agreement enhances Solvay's...

Campine NV ( EBR:CAMB ) shares have had a horrible month, losing 26% after a relatively good period beforehand. Of...

It's not a stretch to say that Azelis Group NV's ( EBR:AZE ) price-to-earnings (or "P/E") ratio of 14x right now seems...

UCB (ENXTBR:UCB) received FDA approval for KYGEVVI, marking a major step in rare disease treatment. KYGEVVI is the first approved therapy for TK2d, a life-threatening mitochondrial disorder with very limited options. See our latest analysis for UCB. Following the FDA approval for KYGEVVI, UCB's momentum has been building. The share price has climbed nearly 20% year-to-date. After some short-term volatility, the stock's 1-year total shareholder return stands at an impressive 26%. Those who...

Syensqo reported third quarter 2025 earnings, revealing sales of €1.56 billion and net income of €39 million, compared to a third quarter net loss in 2024, despite a year-on-year decline in revenue for both the quarter and nine months ending September 30. The company’s rebound to profitability in the third quarter, following a loss a year earlier, underscores a shift in its performance trend even amid lower sales. We’ll assess how Syensqo’s return to quarterly profit, despite weaker sales,...

Lotus Bakeries was recently added to the Euronext 150 Index, highlighting its growing profile among Europe’s largest listed companies. This milestone can influence share demand as index-tracking funds and institutional investors may adjust holdings to include the company. We’ll now explore how inclusion in a major index could impact Lotus Bakeries’ investment narrative and future institutional interest. AI is about to change healthcare. These 32 stocks are working on everything from early...

This week we saw the Banqup Group SA ( EBR:BANQ ) share price climb by 11%. But that doesn't change the fact that the...

Anheuser-Busch InBev announced a US$6 billion share repurchase program and released its third quarter 2025 earnings, reporting sales of US$15.13 billion and net income of US$1.05 billion for the quarter ended September 30, 2025. The board also approved an interim dividend, renewed a key services framework with its Asia-Pacific subsidiary, and disclosed the upcoming departure of its longstanding Chief People Officer, marking a period of significant corporate actions. We'll explore how the...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Key Insights Given the large stake in the stock by institutions, ageas' stock price might be vulnerable to their...

Key Insights The considerable ownership by sovereign wealth funds in bpost/SA indicates that they collectively have a...

As the European market navigates a mixed landscape, with the STOXX Europe 600 Index recently pulling back after reaching new highs and interest rate expectations from the ECB remaining steady, investors are increasingly focused on identifying opportunities among undervalued stocks. In such an environment, a good stock is often characterized by its potential to trade below its estimated intrinsic value, offering room for appreciation as market conditions evolve.

Key Insights The considerable ownership by retail investors in Financière de Tubize indicates that they collectively...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...

Syensqo (ENXTBR:SYENS) shares moved modestly today, catching the eye of investors who are watching for shifts in valuation. The stock’s recent performance offers an interesting angle for those tracking the materials sector. See our latest analysis for Syensqo. Syensqo’s share price has shown some resilience lately, notching a 5.9% gain over the past month and a modest 1-year total shareholder return of 0.6%. While momentum has been somewhat uneven, today’s movement suggests that investors are...

Melexis NV reported its third quarter 2025 results, showing sales of €215.29 million and net income of €27.53 million, both significantly lower than the same period a year ago. The contraction in sales and profit indicates the company may be encountering operational or market challenges over the year so far. We’ll examine how reduced earnings for the quarter are influencing Melexis’ investment narrative and outlook for operational momentum. The end of cancer? These 29 emerging AI stocks are...

DEME Group (ENXTBR:DEME) has won Brazil’s inaugural auction for a port access channel concession, in partnership with FTS Participacoes Societarias. This 25-year contract covers operations and expansion at the vital Port of Parana. See our latest analysis for DEME Group. DEME Group’s announcement of the major Brazilian port concession appears to have reignited market attention, with a strong 6.6% share price return over the past month after a mixed year. While year-to-date returns remain...

Proximus PLC's ( EBR:PROX ) price-to-earnings (or "P/E") ratio of 4.2x might make it look like a strong buy right now...

Anheuser-Busch InBev (ENXTBR:ABI) posted a net profit margin of 12.2% for the most recent period, a jump from last year’s 9.9%. Over the past five years, the company has averaged 24.5% annual earnings growth, with current-year earnings up 20%. Although this is not as rapid as previous years, it is still growing. With analysts forecasting another 10.03% per year in earnings growth and the stock trading well below consensus fair value estimates, investors are likely to see the current...